Literature DB >> 15371818

Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.

Laura S Schmidt1, Michael L Nickerson, Debora Angeloni, Gladys M Glenn, McClellan M Walther, Paul S Albert, Michelle B Warren, Peter L Choyke, Carlos A Torres-Cabala, Maria J Merino, Joan Brunet, Victòria Bérez, Joan Borràs, Giovanni Sesia, Lindsay Middelton, John L Phillips, Catherine Stolle, Berton Zbar, Stephen E Pautler, W Marston Linehan.   

Abstract

PURPOSE: Hereditary papillary renal carcinoma (HPRC) is characterized by a predisposition to multiple, bilateral papillary type 1 renal tumors caused by inherited activating missense mutations in the tyrosine kinase domain of the MET proto-oncogene. In the current study we evaluated the clinical phenotype and germline MET mutation of 3 new HPRC families. We describe the early onset clinical features of HPRC.
MATERIALS AND METHODS: We identified new HPRC families of Italian (family 177), Spanish (family 223) and Cuban (family 268) descent. We evaluated their clinical features, performed MET mutation analysis by denaturing high performance liquid chromatography and DNA sequencing, and estimated age dependent penetrance and survival using Kaplan-Meier analysis. We characterized renal tumors by histology and fluorescence in situ hybridization.
RESULTS: Identical germline MET c.3522G --> A mutations (V1110I) were identified in families 177 and 268 but no evidence of a founder effect was found. Affected members of family 223 carried a germline c.3906G --> C.3522G --> A MET mutation (V1238I). Age dependent penetrance but not survival was significantly earlier for the c.3522G -->A mutation than for the c.3906G --> A mutation in these HPRC families. Trisomy of chromosome 7 and papillary renal carcinoma type 1 histology were detected in papillary renal tumors.
CONCLUSIONS: HPRC can occur in an early onset form. The median age for renal tumor development in these 3 HPRC families was 46 to 63 years. HPRC associated papillary renal tumors may be aggressive and metastasize, leading to mortality. Median survival age was 60 to 70 years. Families with identical germline mutations in MET do not always share a common ancestor. HPRC is characterized by germline mutations in MET and papillary type 1 renal tumor histology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371818     DOI: 10.1097/01.ju.0000139583.63354.e0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  Evaluation and screening for hereditary renal cell cancers.

Authors:  W Marston Linehan
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 2.  Genetic predisposition to kidney cancer.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

Review 3.  Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma.

Authors:  Yuval Freifeld; Lakshmi Ananthakrishnan; Vitaly Margulis
Journal:  Curr Urol Rep       Date:  2018-08-16       Impact factor: 3.092

Review 4.  Kidney cancer pathology in the new context of targeted therapy.

Authors:  Yves Allory; Stéphane Culine; Alexandre de la Taille
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

Review 5.  Signaling pathways in renal cell carcinoma.

Authors:  Gowrishankar Banumathy; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 6.  Renal cell cancers: unveiling the hereditary ones and saving lives-a tailored diagnostic approach.

Authors:  Georgios Kallinikas; Helai Habib; Dimitrios Tsimiliotis; Evangelos Koutsokostas; Barna Bokor
Journal:  Int Urol Nephrol       Date:  2017-05-31       Impact factor: 2.370

Review 7.  The clinical implications of the genetics of renal cell carcinoma.

Authors:  Inger Rosner; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan
Journal:  Urol Oncol       Date:  2009 Mar-Apr       Impact factor: 3.498

Review 8.  Targeting the Met signaling pathway in renal cancer.

Authors:  Alessio Giubellino; W Marston Linehan; Donald P Bottaro
Journal:  Expert Rev Anticancer Ther       Date:  2009-06       Impact factor: 4.512

9.  Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT.

Authors:  Marius George Linguraru; Jianhua Yao; Rabindra Gautam; James Peterson; Zhixi Li; W Marston Linehan; Ronald M Summers
Journal:  Pattern Recognit       Date:  2009-06-01       Impact factor: 7.740

Review 10.  Hereditary kidney cancer: unique opportunity for disease-based therapy.

Authors:  W Marston Linehan; Peter A Pinto; Gennady Bratslavsky; Elizabeth Pfaffenroth; Maria Merino; Cathy D Vocke; Jorge R Toro; Donald Bottaro; Len Neckers; Laura S Schmidt; Ramaprasad Srinivasan
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.